University of Jyvaskyla   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Jyväskylä Finland (1934)

Organization Overview

First Clinical Trial
2015
NCT02367547
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

PROF, UNIVERSITY OF JYVÄSKYLÄ | University of Jyvaskyla | University of Jyväskylä, Finland | University of Jyväskylä, Replicon Health Oy

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Basal Cell (Phase 2)

Neoplasms, Basal Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4